Ulcerative Colitis Clinical Trials
Here are the 6 most popular medical studies for ulcerative colitis
Sphingosine 1-phosphate receptor modulator
Ozanimod for Ulcerative Colitis
“ I have been taking Mesalamine for several years now and have recently been experiencing debilitating flare-ups. I would like to try and see what other treatments are out there.”
UC Clinical Trials
View 96 UC medical studies.
VTX002 for Ulcerative Colitis
This trial is testing a new drug to see if it's safe and effective in treating moderate to severe ulcerative colitis. Up to 180 participants will be given the new drug daily for 28 days to 13 weeks, and then followed for up to 36 months.
Crohn's Disease Clinical Trials
View 9 Crohn's Disease medical studies.
Phase 3 Ulcerative Colitis Clinical Trials
View 97 phase 3 ulcerative colitis medical studies.
Ulcerative Colitis Clinical Trials With No Placebo
View 97 ulcerative colitis medical studies that do not have a placebo group.
View More Ulcerative Colitis Trials
See another 74 many medical studies focused on ulcerative colitis.
Frequently Asked Questions
Introduction to ulcerative colitis
What are the top hospitals conducting ulcerative colitis research?
For individuals living with ulcerative colitis, finding effective treatments and potential breakthroughs is of paramount importance. In the city of Tyler, Texas, the Tyler Research Institute leads the way in clinical trials for this condition. With a remarkable nine ongoing trials and a total of 21 completed studies dedicated to ulcerative colitis, this institute has been at the forefront since their first recorded trial in 2012.
Meanwhile, in Chesterfield, Michigan, the Clinical Research Institute of Michigan is making significant strides as well. They currently have eight active clinical trials focused on ulcerative colitis and have conducted an impressive 25 studies to date since initiating their inaugural trial back in 2004.
Heading south to Naples, Florida, we find another prominent player in gastroenterological research: The Gastroenterology Group of Naples. With six active trials and a history that includes 22 previously conducted studies since launching their first ulcerative colitis trial in 2008 they continue to contribute significantly towards advancements in treatment options.
Notably contributing from Nashville is Vanderbilt University Medical Center where they are conducting six active clinical tests related specifically to ulcerative colitis; adding up over three decades worth through thirty-one previous examinations carried out ever since starting its trial runs precisely seventeen years ago (in2004).
Lastly joining this list is Chevy Chase Clinical Research located at Chevy Chase MD which presently accommodates half-a-dozen ulcers-colon affiliated exploratory endeavors furthermore establishing twenty-three such .surgeries marked within fifteen years since beginning its evaluation forms just five years after (in2006).
These hospitals serve as beacons of hope for those affected by ulcerative colitis worldwide. Their dedication to research brings us closer each day not only toward better understanding but also more effective treatments for this chronic inflammatory bowel disease.
Which are the best cities for ulcerative colitis clinical trials?
When it comes to ulcerative colitis clinical trials, several cities emerge as leading hubs for research and development. New York City boasts 50 active trials, focusing on promising treatments like tofacitinib, Ozanimod, and risankizumab. Miami, Florida follows closely with 44 ongoing studies exploring interventions such as ABX464 50mg and Upadacitinib (ABT-494). Houston, Texas also stands out with 40 active trials investigating treatments like Ozanimod and Mirikizumab. These cities offer individuals with ulcerative colitis access to cutting-edge clinical trials that fuel advancements in care and bring hope for improved outcomes.
Which are the top treatments for ulcerative colitis being explored in clinical trials?
Exciting progress is being made in the realm of ulcerative colitis treatments, with several promising contenders emerging from clinical trials. Leading the pack is etrasimod, currently undergoing testing in three active trials and amassing a total of 10 all-time studies dedicated to addressing this condition since its debut in 2015. Mirikizumab follows closely behind, also participating in three ongoing trials and accumulating six all-time ulcerative colitis0 all-time studies dedicated to addressing this condition since its debut in 2015. Mirikizumab follows closely behind, also participating in three ongoing trials and accumulating six all-time ulcerative colitis studies since its introduction in 2015. Additionally, ozanimod shows promise with two active trials and eight all-time evaluations for ulcerative colitis since its listing began in 2012. Finally, vedolizumab remains an important contender with two ongoing trials and an impressive history of 24 overall investigations focusing on ulcerative colitis treatment since it was first listed back in 2007. These innovative therapies bring hope for improved outcomes for individuals battling this challenging disease.
What are the most recent clinical trials for ulcerative colitis?
Exciting developments are underway in the field of ulcerative colitis treatment, with recent clinical trials offering new possibilities for patients. One such trial is focusing on an open-label induction phase to evaluate the efficacy and safety of a potential treatment for ulcerative colitis. Another study explores the combination of oral Upadacitinib with methylprednisolone plus cyclosporine infusion as a therapeutic approach for this condition. Additionally, high-dose budesonide is being investigated in another trial to assess its effectiveness in managing symptoms related to ulcerative colitis. The introduction of PRIM-DJ2727 - FROZEN and mirikizumab also bring hope as potential therapies undergoing Phase 1 and Phase 3 evaluations respectively, aiming to improve outcomes for individuals living with ulcerative colitis.
What ulcerative colitis clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of ulcerative colitis research. Notably, Bacainn Therapeutics, Inc. completed a trial investigating the effectiveness of BT051 200 mg in November 2021. Earlier in June 2021, Bridge Biotherapeutics, Inc.'s study on BBT-401-1S concluded with promising results. In May 2021, Landos Biopharma Inc.'s NX-13 250mg IR trial also reached completion and showed encouraging outcomes. These achievements highlight the dedication of various pharmaceutical companies to developing innovative therapies for patients suffering from ulcerative colitis.